Compare Schwab US Dividend Equity ETF (SCHD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs TransMedics Group Inc — how do they compare? Schwab US Dividend Equity ETF trades at $34.23, while TransMedics Group Inc trades at $87.42 (market cap $3.10B). The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SCHD | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $34.27 | $150.42 |
52-Week Low | $26.44 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $34.225, up 0.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's dividend strategy remains a core appeal, highlighted by a scheduled $0.25 dividend in June 2026. Recent news emphasizes its role in retirement income portfolios and institutional accumulation, such as Barry Investment Advisors increasing its stake by 29.9% in Q2 2026.
Outlook is supported by dividend reliability and value rotation trends, but risks include yield competition from Treasuries and tax inefficiencies in taxable accounts. The ETF suits income-focused investors seeking steady payouts, though overbought conditions may limit near-term gains.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
